MINIject in Glaucoma Today

In the latest issue of Glaucoma Today, iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM features as the only therapy currently available that reestablishes the physiological drainage pathway through the supraciliary route.

Read more

CEO Michel Vanbrabant to present at OIS Glaucoma virtual 2021

iSTAR Medical was selected to present the latest data for MINIjectTM, its minimally-invasive glaucoma surgery (MIGS) device, at the OIS Glaucoma Innovation Showcase on 21st October 2021 at 1:20PM EDT.

Read more

MINIjectTM longer-term data at ESCRS

The latest results from the European STAR-II trial of MINIjectTM, iSTAR Medical’s minimally invasive glaucoma surgery device (MIGS), will be presented at the 39th edition of the European Society of Cataract and Refractive Surgeons (ESCRS) annual meeting. ESCRS is taking place between October 8 and 11 in Amsterdam, the Netherlands.

Professor Julián García Feijoó, Universidad Complutense, Madrid Spain, and one of the STAR-II trial investigators, will present the positive 18-month efficacy and safety data from STAR-II and discuss them live on Monday 11 October at 12:30 CET in Hall 9.

In addition, promising preliminary, interim three-year data on MINIjectTM from the STAR-I trial will be presented ‘on-demand’ by Professor Philippe Denis, Hôpital de la Croix-Rousse, Lyon, France (Poster ID: PP002).

ESCRS is amongst the first international congresses to go back to face-to-face interactions and will take place in a hybrid format this year, including in person and online attendance.

Created with GIMP

iSTAR Medical’s Supraciliary MIGS presented at IGC

MINIjectTM, iSTAR Medical’s minimally invasive glaucoma surgery (MIGS) device, will be presented as part of the “On the Cutting Edge” talks during the opening session at the prestigious, invitation-only Interventional Glaucoma Congress (IGC) meeting in Chicago from 7 to 11 October 2021. Dr Brian Flowers, who will present iSTAR Medical’s technology, specializes in glaucoma and cataracts at Ophthalmology Associates, in Fort Worth, Texas, and is one of the implanting surgeons in MINIject trials.

Dr Flowers will speak to the top 100 glaucoma surgeons in North America about how MINIjectTM differs from other MIGS due to its proprietary STAR® material, and will present the latest clinical data from MINIjectTM trials. On 15 July 2021, iSTAR Medical announced FDA approval for a pivotal trial for MINIjectTM in glaucoma patients in the United States.

The IGC meeting is an invitation-only, think tank–style meeting for glaucoma specialists to exchange ideas on innovations and advanced practices for improved patient care. It is chaired by glaucoma specialists Doctors Ike Ahmed, Richard Lewis and Arsham Sheybani.

Image IGC Brian Flowers

MINIject’s data presented at European Ophthalmology Futures Forum, Virtual 2021

iSTAR Medical was selected for a presentation at the virtual European Ophthalmology Futures Forum this Thursday 7 October, where CEO Michel Vanbrabant will present competitive strengths for iSTAR Medical’s revolutionary MIGS device MINIjectTM.

Read more

Preliminary, interim, three-year MINIjectTM data show strong performance and no ECD safety concerns

Promising preliminary, interim three-year data on iSTAR Medical’s Minimally Invasive Glaucoma Surgery (MIGS) device, MINIjectTM, showed strong performance and no endothelial cell density (ECD) safety concerns in glaucoma patients, confirming the positive trend observed so far as part of the STAR-I trial.

The data have been presented at the Deutsche Ophthalmologische Gesellschaft (DOG) congress, the annual meeting of the German Ophthalmology Society, by Professor Christoph Hirneiss, Ludwig-Maximilians University, Munich, Germany.

In addition, 18-month data from the European STAR-II trial have been presented at the DOG meeting by Professor Burkhard Dick, Head of the University Eye Clinic Bochum, and one of the five German trial centres participating in the study. The data showed strong performance in intraocular pressure (IOP) and medication reduction at 18-month follow-up, in line with the STAR-I results at the same timepoint, and no safety concerns with corneal endothelial cell density.

“Based on performance and safety data seen so far, this supraciliary MIGS procedure offers a valuable bleb-free treatment option for patients with glaucoma requiring low target pressures,” said Professor Burkhard Dick.

Dick

Hirneiss

MINIjectTM data featuring at German DOG virtual meeting

Results from MINIject’s European STAR-II trial and from the long-term follow-up trial STAR-GLOBAL will feature at the Deutsche Ophthalmologische Gesellschaft (DOG) congress, the annual meeting of the German Ophthalmology Society taking place 30 September to 3 October.

The 18-month data from the European STAR-II trial will be presented on-demand by the global leading ophthalmologist, Professor Burkhard Dick, Head of the University Eye Clinic Bochum, and one of the five German trial centres participating in the study.

Preliminary, interim three-year data from the STAR-GLOBAL study will be revealed in a presentation by Professor Christoph Hirneiss (Ludwig-Maximilians University, Munich, Germany) on Saturday 2nd October at 09:14 on channel 2 in the session “Glaucoma Surgery – Where are we heading?”, followed by live questions and answers.

Web

MINIject interim three-year data to be presented at WGC-2021

Interim three-year data on iSTAR Medical’s Minimally Invasive Glaucoma Surgery (MIGS) device MINIjectTM will be presented at the World Glaucoma Congress WGC-21, virtually hosted by the Japan Glaucoma Society between 30th June and 3rd July.

Read more

Prof. Dr Christoph Hirneiß presents MINIject at DOC 2021 digital

The DOC (Deutsche Gesellschaft für Ophthalmochirurgie e.V.) are holding their 33rd International Congress of German Ophthalmic Surgeons as a digital event this year from 17 to 19 June 2021. The congress includes an extensive programme with scientific sessions on glaucoma surgery.

Read more

MINIject presented at MIGS Symposium 2021

MINIjectTM, iSTAR Medical’s minimally invasive glaucoma surgery (MIGS) device, will be presented in two lectures at the upcoming MIGS Symposium 2021 on Saturday, 17th April from 11:00AM to 2:30PM CET.

Read more